A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Alcon Research1 site in 1 country87 target enrollmentNovember 2005

ConditionsOpen-angle Glaucoma Ocular Hypertension

InterventionsAL-37807 Ophthalmic Suspension, 1.0%Latanoprost, 0.005% (Xalatan)AL-37807 Vehicle Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%

DrugsAL-37807 Ophthalmic Suspension, 1.0%Latanoprost, 0.005% (Xalatan)Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%

Overview

Phase: Phase 2
Intervention: AL-37807 Ophthalmic Suspension, 1.0%
Conditions: Open-angle Glaucoma
Sponsor: Alcon Research
Enrollment: 87
Locations: 1
Primary Endpoint: Mean intra-ocular pressure (IOP) change at Day 28 from baseline (Day 0)
Status: Completed
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.

Registry

clinicaltrials.gov

Start Date

November 2005

End Date

February 2006

Last Updated

14 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Alcon Research

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Diagnosed with open-angle glaucoma (with ot without pseudoexfoliation or pigment dispersion component) or ocular hypertension
•Other protocol-defined inclusion criteria may apply.